CLK1 and breast carcinoma: Using mass spectrometric analyses, we found that most elevated proteins in Ki8751-treated cancers were all mitochondrial proteins, namely NDFIP1, CLK1, and TEFM, suggesting that Ki8751 treatments may enhance mitochondrial biogenesis of breast cancer cells.